Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Updated analysis of adjuvant chemotherapy after radical resection of metachronous colorectal cancer metastases.

Sevindzh Evdokimova, Anna Kornietskaya, Larisa Bolotina et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15618

e15618 Background: The role of adjuvant systemic therapy following complete (R0) resection of metachronous colorectal canc...

A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.

Judy S. Wang, Ildefonso I. Rodriguez Rivera, Deepak Bhamidipati et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3167

TPS3167 Background: ATX-295 is an oral inhibitor of KIF18A, an adenosine triphosphate (ATP)-dependent, plus end-directed m...

Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.

Petros Grivas, Begoña P. Valderrama, Marinos Tsiatas et al. Jun 01, 2026 pp. 4568-4568 10.1200/jco.2026.44.16_suppl.4568

4568 Background: Ave 1L maintenance is a recommended treatment option for patients (pts) with aUC without progression afte...

Impact of earlier time of first cycle immunotherapy administration on progression-free survival in real-world metastatic non–small cell lung cancer.

Brendon Fusco, Mumtu Lalla, Puneet Dhillon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20579

e20579 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung c...

Pulmonary embolism-related mortality in pancreatic cancer patients aged ≥45 years in the United States, 1999-2023: A CDC WONDER analysis.

Dileep Raja Kuraku, Nagarjuna Keshapogu, Karthik Kanna Venkatesh Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16411

e16411 Background: Pancreatic cancer is among the most prothrombotic malignancies; however, long-term national trends in p...

Predictors of persistent opioid use following curative-intent radiation for head and neck cancer.

Alec Kotler, Om Desai, Kevin Agner et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18099

e18099 Background: Head and neck cancer (HNC) patients often experience pain from intense radiation treatment. Opioids wor...

Anal cancer incidence among Medicaid enrollees with HIV in the United States.

Ashish Deshmukh, Ketki N. Borse, Grace Xu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16479

e16479 Background: Anal cancer incidence remains elevated among people with HIV (PWH); however, incidence among PWH enroll...

Comprehensive genomic profiling of adenoid cystic carcinoma using the AACR Genie Database.

Madeline Patrick, David Maliy, Amber Chang et al. Jun 01, 2026 pp. 6072-6072 10.1200/jco.2026.44.16_suppl.6072

6072 Background: Adenoid cystic carcinoma (ACC) is a rare neoplasm of the secretory glands, comprising <1% of head and...

Financial toxicity and care access barriers among adolescent and young adult versus older melanoma survivors: A population-based analysis of 2021-2024 National Health Interview Survey data.

Vanshika Singh, Jay Tewari, Priyam Nayak et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21592

e21592 Background: Adolescent and young adult (AYA) cancer survivors may experience disproportionate financial toxicity an...

U.S. patient enrollment in pivotal clinical trials that supported FDA oncology approvals from 2020 to 2025.

Oladimeji Akinboro, Abhilasha Nair, Romeo Angelo M. DeClaro Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23030

e23030 Background: Adequate enrollment of U.S. patients in pivotal clinical trials designed to support applications for FD...

Clinical outcomes in <i>TP53</i> -mutated clonal hematopoiesis: Single-center retrospective study.

Jacob Edward Herstein, Manuel Maroun, Guillermo Montalban-Bravo et al. Jun 01, 2026 pp. 6594-6594 10.1200/jco.2026.44.16_suppl.6594

6594 Background: Clonal hematopoiesis (CH), including CH of indeterminate potential (CHIP) and clonal cytopenia of undeter...

Suicide gene therapy for recurrent glioblastoma using allogeneic bone marrow–derived mesenchymal stem cell gene delivery (MSC/CD): A first-in-human, dose-escalation phase I clinical trial.

Jaejoon Lim, JeongMin Sim, Ju-Won Kim et al. Jun 01, 2026 pp. 2071-2071 10.1200/jco.2026.44.16_suppl.2071

2071 Background: Glioblastoma (GBM) remains an incurable brain tumor characterized by complex heterogeneity and poor progn...

Clinical and molecular landscape of MTAP-deleted thoracic tumors across Western and Asian cohorts: Implications for synthetic lethal targeting.

Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki-Ushiku et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20713

e20713 Background: Methylthioadenosine phosphorylase (MTAP) deletion creates a synthetic lethal vulnerability to protein a...

Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.

Amama Ali, Massimo Cristofanilli, Carolina Reduzzi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15060

e15060 Background: In metastatic Breast Cancer (mBC) Circulating Tumor Cells (CTCs) are an established prognostic indicato...

Cost-saving analysis of neoadjuvant versus adjuvant immunotherapy in clinical stage III melanoma: A real-world Brazilian perspective.

Ana Paula Beck da Silva Etges, Milton Jose De Barros E. Silva, Aline Chibana et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21544

e21544 Background: Neoadjuvant immunotherapy has become a new standard for resectable clinical stage III melanoma, driven...

Clinical factors associated with durable response to atezolizumab in extensive-stage small-cell lung cancer: A real-world analysis in Moscow.

Evgenia Khatkova, Demid Shchetinkin, Elizaveta Lukashova et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20160

e20160 Background: Atezolizumab (A) in combination with platinum-etoposide chemotherapy represents the current standard of...

Real-world efficacy and safety of sintilimab combined with nab-paclitaxel and S-1 as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: A single-center retrospective study.

Song Meiqi, Yuanzhi Guo, Yue Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16373

e16373 Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis, and effective first-line t...

Has racial and ethnic representation in oncology clinical trials changed?: A 30-year systematic analysis using artificial intelligence.

Rahman Adesoji Olusoji, Marcos J.G. De Lima, Bradley Wayne Blaser et al. Jun 01, 2026 pp. 11079-11079 10.1200/jco.2026.44.16_suppl.11079

11079 Background: Despite societal emphasis on racial and ethnic representation in oncology trials, it remains unclear whe...

Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force.

Michael Mitchell, Yingchao Yuan, Arlene Naranjo et al. Jun 01, 2026 pp. 10007-10007 10.1200/jco.2026.44.16_suppl.10007

10007 Background: Patients with metastatic neuroblastoma confined to distant lymph nodes (4N) were identified as a subgrou...

Health-related quality of life.

Erinne Wasalski, J. Scott Parrott, Shashi Mehta Jun 01, 2026 pp. 1109-1109 10.1200/jco.2026.44.16_suppl.1109

1109 Background: Trials typically pool patient-reported outcomes across demographics, assuming baseline differences reflec...

Real-world outcomes of immune checkpoint inhibitors in patients aged 65–74 versus ≥75 years with non-small cell lung cancer.

Sameeha Sajid, Muhammad Daud Abdullah, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20642

e20642 Background: Immune Checkpoint Inhibitors (ICIs) have shown significant survival benefit in the treatment of Non-Sma...

Major adverse cardiovascular events in androgen receptor signaling inhibitor–treated patients with metastatic castration-sensitive prostate cancer.

Linden Huhmann, Jennifer La, Karlynn Dulberger et al. Jun 01, 2026 pp. 5107-5107 10.1200/jco.2026.44.16_suppl.5107

5107 Background: Cardiovascular disease is highly prevalent in the predominantly older male population with metastatic cas...

PUNCH03: Preliminary results from a phase II study of disitamab vedotin combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Zongren Wang, Bin Huang, Cheng Luo et al. Jun 01, 2026 pp. 4597-4597 10.1200/jco.2026.44.16_suppl.4597

4597 Background: Disitamab vedotin (RC48) was a novel antibody drug conjugate that targets the Her2 protein. The KEYNOTE-0...

Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.

Mohammad Saad Farooq, Caitlyn Balsay-Patel, Stanley P. L. Leong et al. Jun 01, 2026 pp. 9568-9568 10.1200/jco.2026.44.16_suppl.9568

9568 Background: Stage IIB/C cutaneous melanoma is associated with high recurrence risk, however stratification of risk in...

The impact of surgery and the type of immune check point inhibitors (ICI) in patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) receiving immunotherapy: An updated systematic review and meta-analysis of randomized controlled trials.

Abbas Hussain, Khadija Mohib, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18081

e18081 Background: Locally advanced head and neck squamous cell carcinoma (LA HNSCC) remains a clinical challenge with hig...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page